NCT07290699 — drugset

Summary

This project team is conducting a multicenter randomized controlled study, aiming to administer PCSK9 inhibitors subcutaneously as early as possible within 24 hours during the perioperative period of AMI (included \<24h STEMI and NSTEMI), and subsequently once every 12 weeks for a total of 6 months, followed by step-down therapy according to guideline-recommended lipid-lowering strategies based on LDL-C target levels. The study will evaluate changes in blood lipids and inflammatory markers during hospitalization and at follow-up visits at 1, 3, 6, 9, and 12 months, as well as the incidence of MACE events. Safety will also be assessed, including liver enzymes, kidney function, and other adverse reactions. Compared with conventional treatment, the study will test efficacy and ultimately clarify that early combined use of PCSK9 inhibitors during the perioperative period of AMI patients can safely and effectively reduce LDL-C, control systemic inflammatory responses, and improve the incidence of MACE events.

Timeline

Start: 2026-01-01
Primary completion: 2027-08-30
Completion: 2028-08-30

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Recaticimab	Monoclonal antibody	450 mg	Subcutaneous

Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period

Summary

Timeline

Publications

Drugs

Indications